webinar register page

ISGH Faculty Research Presentation: Jamie Feldman, MD, PhD, and Johanna Back, MS-3 present: Gender, Sex at Birth, and Estimated COVID 19 Complication Risks

Sex assigned at birth and gender appear to affect both the risk and acute complications from COVID-19 infection, as indicated in studies among cisgender men and women. COVID-19 estimated risk scores have included include “sex” as a factor, but not gender, with variable definitions of “sex.” No studies have examined the estimated or actual risk of acute complications in transgender patients receiving hormone therapy. This presents a significant gap in 1) understanding the role of hormones in COVID-19 infection; 2) COVID-19 risks faced by a population already facing health disparities; and 3) the effect of social, legal and medical conflations of “sex” and “gender” in health care measures.

During this presentation, we will present preliminary results of a retrospective chart review of 619 adult transgender and gender diverse persons receiving gender affirming hormone therapy from 2012 to 2021. This study examines the relationships among the estimated COVID risk (MASSBP) score, sex assigned at birth gender identity, and documented legal gender marker change, duration of hormone therapy and documented COVID tests, infections and vaccination.

The following team members participated in this conduct of this study, analysis and interpretation of this data and provided feedback on this presentation: Jamie Feldman, MD, PhD, and Johanna Back, MS-3.

Apr 4, 2023 12:00 PM in Central Time (US and Canada)